
Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) shares are trading higher Monday after the company announced top-line data from its crossover bioavailability trial assessing its investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults.
What To Know: The company said its new under-the-tongue aspirin product for suspected heart attacks worked faster and more effectively than standard chewed aspirin in the study. The treatment was safe and well-tolerated, with no side effects reported.